Previous Article | Next Article 
Journal of Virology, July 2000, p. 6300-6308, Vol. 74, No. 14
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Isolation and Characterization of Monoclonal
Antibodies That Inhibit Hepatitis C Virus NS3 Protease
Takamasa
Ueno,1,*
Satoru
Misawa,1
Yoichi
Ohba,1
Mitsuhiro
Matsumoto,1
Makiko
Mizunuma,1
Nobuhiro
Kasai,2
Kouhei
Tsumoto,2
Izumi
Kumagai,2 and
Hideya
Hayashi1
Pharmaceuticals & Biotechnology Laboratory,
Japan Energy Corporation, Toda-shi, Saitama,
335-8502,1 and Department of
Biomolecular Engineering, Graduate School of Engineering, Tohoku
University, Aoba-yama, Sendai 980-8579,2 Japan
Received 10 January 2000/Accepted 24 April 2000
 |
ABSTRACT |
A series of mouse monoclonal antibodies (MAbs) to the nonstructural
protein 3 (NS3) of hepatitis C virus was prepared. One of these MAbs,
designated 8D4, was found to inhibit NS3 protease activity. This
inhibition was competitive with respect to the substrate peptide
(Ki = 39 nM) but was significantly decreased by
the addition of the NS4A peptide, a coactivator of the NS3 protease.
8D4 also showed marked inhibition of the NS3-dependent cis processing of the NS3/4A polyprotein but had virtually
no effect on the succeeding NS3/4A-dependent trans
processing of the NS5A/5B polyprotein in vitro. Epitope mapping of 8D4
with a random peptide library revealed a consensus sequence, DxDLV, that matched residues 79 to 83 (DQDLV) of NS3, a region containing the
catalytic residue Asp-81. Furthermore, synthetic peptides including
this sequence were shown to block the ability of 8D4 to bind to NS3,
indicating that 8D4 interacts with the catalytic region of NS3. The
data showing decreased inhibition potency of 8D4 against the NS3/4A
complex suggest that 8D4 recognizes the conformational state of the
protease active site caused by the association of NS4A with the protease.
 |
INTRODUCTION |
Nonstructural protein 3 (NS3) of
hepatitis C virus (HCV) is a multifunctional virus-specific protein
that contains serine protease activity in its N-terminal region and
accounts for processing of the viral polyprotein at four cleavage
sites, NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B, whereas helicase and
nucleic acid-stimulated nucleoside triphosphatase activities are found
in its C-terminal region (see references 2 and
23 for reviews). The NS3 protease requires the NS4A
protein as a cofactor for efficient cleavage of the polyprotein
(35, 39). Because this enzyme plays an obligatory role in
viral replication, it provides a logical target for the development of
potentially selective antiviral agents. Development of increasingly
specific inhibitors of NS3 requires detailed knowledge of the tertiary
structure of the enzyme. X-ray crystallographic analysis (21, 28,
29, 41) and nuclear magnetic resonance (NMR) spectroscopic
analysis (1, 6) of the NS3 protease domain with or without
the NS4A cofactor have provided a refined picture of the NS3 structure.
Those studies show that the overall topology of NS3 protease is similar
to that of chymotrypsin-like serine proteases and NS3 forms N-terminal (approximately residues 1 to 93) and C-terminal (residues 94 to 180)
six-stranded antiparallel
-barrels that are packed like those of
chymotrypsin-like serine proteases (1, 6, 21, 28, 29, 41).
The catalytic site of NS3 protease is formed by the triad of residues
His-57, Asp-81, and Ser-139 and is found in the crevice between the two
barrels. The interaction of NS4A with NS3 was shown to induce
conformational changes in NS3 that involve both a structural
reorganization of the N-terminal domain and a rearrangement of the
protease catalytic site including Asp-81 (1, 21, 29).
Although the tertiary structure of NS3 protease has been defined in
detail, several loops found in other chymotrypsin family proteases,
which play a critical role in defining the shapes of the non-prime-side
substrate-binding pockets, are missing from NS3, rendering the
substrate-binding groove relatively featureless and therefore making
the design of low-molecular-weight inhibitors quite challenging
(21). As an alternative approach to the study of structure
and for designing inhibitors of NS3 protease, we have prepared a series
of monoclonal antibodies (MAbs) for use in probing the tertiary
conformation of the enzyme with or without the NS4A cofactor. In the
present study, we describe the isolation and characterization of the
MAbs designated 7E3, 7E9, and 8D4. One of these MAbs, 8D4, appears to
be a competitive inhibitor with respect to the substrate peptide and
recognizes a linear surface epitope containing residues 79 to 83 of
NS3, a region containing the catalytic residue Asp-81.
 |
MATERIALS AND METHODS |
Preparation of MAbs.
Inclusion bodies formed upon
overproduction of the N-terminal protease domain of the NS3 protein
(NS31-160) in Escherichia coli strain SCS1 were
dissolved in 8 M urea, 50 mM Tris-HCl (pH 8.5), and 1 mM EDTA.
NS31-160 protein was then purified by gel filtration
chromatography (Sephacryl S-200 HR; Pharmacia) in the presence of 8 M
urea, dialyzed against distilled water, and lyophilized. Since we could
not obtain any MAb specific for the N-terminal protease domain of the
NS3 protein when the full-length NS3 protein had been used to immunize
mice, we used NS31-160 instead as an immunogen in this
study, although this preparation showed no protease activity even after
urea was removed by dialysis (data not shown).
Five 6-week-old BALB/c mice were then immunized at 2-week intervals
with the NS31-160 protein (approximately 100 or 250 µg
of protein per injection) emulsified with Freund's complete adjuvant
(Difco Laboratories) for the first injection and incomplete adjuvant
for the two subsequent injections. Sera were tested by enzyme-linked
immunosorbent assay (ELISA) and Western blotting as described below.
Spleen cells from the mouse showing the strongest reaction were then
fused with the mouse myeloma cell line P3X63Ag8U1. Colony supernatants
were screened by ELISA with 96-well microtiter plates that had been
coated with approximately 0.1 µg of purified NS31-160.
The positive supernatants were further tested by Western blotting, and
the corresponding hybridomas were cloned by limiting dilution.
Production and purification of active NS3 protease.
DNA
fragments encoding the full length (1 to 631 residues) and N-terminal
protease domain (1 to 190 residues) of NS3 of HCV IIJ
(20) were cloned into the expression vector pMAL-c2 (New England Biolabs) and pMT1, which had been constructed by replacing the
tac promoter of pMK2 (17) with the tryptophan
promoter, respectively, in order to overproduce a maltose-binding
protein-NS3 protease (MBP-NS31-631) fusion protein
and an N-terminal domain with a hexahistidine tag
(His6-NS31-190), respectively. For
MBP-NS31-631 production, E. coli (strain
HB101) cells transformed with the resulting plasmid were cultured
overnight in ampicillin (100 µg/ml)-containing 2× YT medium (1.6 g
of tryptone, 1 g of yeast extract, and 0.5 g of NaCl per
liter of distilled water), further propagated in the same medium (2 liters) to the mid-logarithmic growth phase at 30°C, and then exposed
to 1 mM isopropyl-1-thio-
-D-galactoside and cultured for
an additional 15 h at 25°C. Cells were then harvested, suspended
in buffer (20 mM Tris-HCl [pH 7.4], 0.2 M NaCl, 1 mM EDTA), and
disrupted by sonication on ice. MBP-NS31-631 was purified
by affinity chromatography with amylose resin (New England Biolabs),
followed by gel filtration chromatography (Sephacryl S-300 HR;
Pharmacia) in order to remove improperly folded species. Fractions
containing NS3 protease activity were collected and pooled in a buffer
containing 20 mM sodium phosphate, pH 7.2. For
His6-NS31-190 production, E. coli
(strain JM109) cells transformed with the resulting plasmid were
cultured overnight in ampicillin (100 µg/ml)-containing M9 medium (60 g of Na2HPO4, 30 g of
KH2PO4, 10 g of NH4Cl, 5 g of NaCl per liter of distilled water, pH 7.4) supplemented with 0.2% Casamino Acids, 0.2% glucose, 1 mM MgSO4, 0.1 mM
CaCl2, and 1 mM thiamine, further propagated in the same
medium (3.6 liters) for 15 h, and then exposed to 25 µg of
3-indoleacrylic acid/ml and cultured for an additional 8 h at
20°C. Cells were then harvested, suspended in buffer (50 mM Tris-HCl
[pH 7.5], 0.3 M NaCl, 20 mM imidazole, 10% glycerol), and disrupted
by sonication on ice. His6-NS31-190 was then
purified by metal chelate affinity (Ni-NTA Superflow; Qiagen) and ion
exchange chromatographies (S-Sepharose Fastflow; Pharmacia). Fractions
containing NS3 protease activity were collected and pooled in a buffer
containing 50 mM Tris-HCl (pH 7.5), 10% glycerol, and 0.5%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS).
Both NS3 proteases thus prepared showed >90% purity as assessed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(data not shown) and were stored at
70°C after the addition of an
equal volume of glycerol.
Enzymatic assays for NS3 protease activity.
When a synthetic
peptide carrying the NS5A/5B cleavage site and having a fluorescent
moiety at its N terminus (2-aminobenzoyl [Abz]-EDVVECSMSY-NH2) was used as a substrate, the
reaction mixture contained 50 mM Tris-HCl (pH 8.5), 30 mM NaCl, 5 mM
CaCl2, and 10% glycerol or 50 mM Tris-HCl (pH 8.5), 30 mM
NaCl, 2% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate and 5% glycerol for MBP-NS31-631 or
His6-NS31-190, respectively. Either of the NS3
proteases was preincubated in the presence or absence of MAbs and the
NS4A peptide (H-LTTGSVVIVGRIILSGRPAVVPD-OH [Pep4A18-40]) (35) for 10 min at room
temperature in a total volume of 80 µl. The reaction was initiated by
the addition of 20 µl of the substrate peptide dissolved in 50 mM
Tris-HCl (pH 8.5), 30 mM NaCl, 5 mM CaCl2, and 25 mM
dithiothreitol. The final concentration of the peptide substrate in the
reaction mixture was 0.025 or 0.2 mM, unless otherwise indicated, when
in the presence or absence of Pep4A18-40, respectively. It
was continued at 37°C for 15 or 60 min with or without
Pep4A18-40, respectively, and was quenched by the addition
of 100 µl of 0.5% trifluoroacetic acid (TFA). The fluorescent
reaction product (Abz-EDVVEC-OH) was then separated on a reversed-phase
high-pressure liquid chromatography (HPLC) apparatus equipped with a
C4 column (4.6 by 50 mm; Vydac) by elution at a flow rate
of 2 ml/min with an aqueous solution containing 14% acetonitrile and
0.1% TFA, and the fluorescence signal was detected by a
spectrofluorometric detector (Shimadzu, Kyoto, Japan) with excitation
and emission wavelengths at 320 and 425 nm, respectively. The product
was quantified by integration of the chromatogram with respect to the
chemically synthesized peptide standard with a structure identical to
that of the cleavage product. Steady-state kinetic parameters and the
Ki value were determined by Lineweaver-Burk plot
and Dixon plot analyses, respectively. All peptides used for enzymatic
assays were synthesized and purified by HPLC by the Peptide Institute
Inc. (Osaka, Japan).
To examine the NS3 protease activity toward in vitro-translated
substrates, we synthesized radiolabeled NS3/4A (for
cis
processing)
and NS5A/5B (for
trans processing) polyproteins
by using a coupled
transcription-translation system (TNT rabbit
reticulocyte lysate
system; Promega) according to the manufacturer's
protocol. DNA
fragments encoding NS3/4A and NS5A/5B cleavage sites,
which encompassed
residues 1027 to 1711 and 2320 to 3011, respectively,
of the HCV-II
J polyprotein, were cloned into the plasmid
pTZ18U (Pharmacia) downstream
of the T7 promoter to generate pTZNS3-4K
and pTZNS5, respectively.
For the
cis-processing assay, 1 µg of pTZNS3-4K was added to 50
µl of the TNT reaction mixture
containing 40 µCi of [
35S]methionine (1,000 Ci/mmol;
Amersham) in the presence or absence
of MAbs and incubated at 30°C
for 90 min. For the
trans-processing
assay, NS3/4A protease,
which had been translated without radiolabel
in vitro, was first
preincubated at 30°C for 10 min in the presence
or absence of MAbs.
The reaction was then initiated by the addition
of a radiolabeled
polyprotein containing the NS5A/5B cleavage
site and was incubated at
30°C for 2 h. For both assays, reactions
were quenched by the
addition of an equal volume of 2× SDS-sample
buffer (62.5 mM Tris-HCl,
2% SDS, 25% glycerol, 0.3 M 2-mercaptoethanol,
0.01% bromophenol
blue) and the products were separated by SDS-PAGE.
The amounts of the
products were integrated and analyzed with
a phosphoimager instrument
(BAS 2000; Fuji Photo Film, Tokyo,
Japan).
Interaction of antibodies with NS3 protein or epitope peptides.
(i) Western blot.
After bacterial cell lysates or purified NS3
proteins had been separated by SDS-PAGE, the proteins were electrically
transferred to a polyvinylidene difluoride membrane (Bio-Rad
Laboratories), and the membrane was preblocked with phosphate-buffered
saline (PBS) containing 5% nonfat dry milk. The resultant membrane was incubated with 10 µg of MAbs/ml for 2 to 8 h at room
temperature, followed by labeling with biotinylated goat anti-mouse
immunoglobulin G (IgG) antibody (Life Technologies Inc.) and
streptavidin-peroxidase conjugate (Tago Inc.). Reactive bands were
stained with a 3,3'-diaminobenzidine peroxidase substrate tablet set
(Sigma). Band intensities were quantified by densitometric analysis
(Atto Corp., Tokyo, Japan) of the blots.
(ii) ELISA.
Ninety-six-well microtiter plates were coated
with an appropriate amount (0.01 to 0.1 µg) of MBP-NS3 protein
dissolved in PBS containing 0.05% Tween 20 and incubated overnight at
4°C. Serially diluted MAbs were then incubated for 1 h at room
temperature. After a thorough washing with PBS-0.05% Tween 20, MAbs
bound to the target antigen were labeled with biotinylated goat
anti-mouse IgG antibody and streptavidin-peroxidase conjugate and
identified with ortho-phenylenediamine as a substrate for
the peroxidase reaction.
(iii) Surface plasmon resonance.
Kinetic analysis of the
interactions of MAbs with NS3 protease was done with an IAsys Auto+
Optical Biosensor instrument (Affinity Sensors, Cambridge, United
Kingdom). Approximately 1.5 µg of MBP-NS31-631 was
immobilized on the carboxymethylated dextran layer via
N-hydroxysuccinimide and
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide chemistry. A coupling
efficiency of 2,800 arc was obtained. For the determination of the
kinetic constants, a diluted solution of MAbs ranging from 30 to 700 nM
was added to the cuvette. Binding traces were recorded for at least
four different concentrations. Association and dissociation rate
constants were calculated by the computer program FASTFIT (Affinity
Sensors) using the association phase.
Epitope mapping.
Random peptide libraries inserted within
the thioredoxin active site loop and displayed on bacterial flagella
(FliTrx; Invitrogen) were used for the determination of epitopes
recognized by these MAbs, as described by Lu et al. (30)
with modifications. A portion (~1010 cells) of
overnight-cultured FliTrx Library in IMC medium (1× M9 salts, 0.2%
Casamino Acids, 0.5% glucose, 1 mM MgCl2, 100-µg/ml ampicillin) at 25°C was further propagated in 50 ml of fresh IMC medium supplemented with 100 µg of tryptophan/ml for an additional 6 h to induce expression of the gene encoding
flagellin-thioredoxin fusion proteins containing the peptide library.
The library-displaying E. coli cells, which had been washed
and resuspended in 0.5 ml of buffer (IMC medium, 150 mM NaCl, 0.2 mg of
bovine serum albumin/ml, 0.4%
-methyl mannoside) were mixed with 20 µg of each of the MAbs. After a 30-min incubation, paramagnetic
microbeads conjugated with goat-anti-mouse IgG (Miltenyi Biotec,
Bergisch Gladbach, Germany) were added. E. coli cells that
bound primary and secondary antibodies with magnetic beads were
separated by magnetic cell sorting technology (32). Cells
enriched by binding to either of three MAbs were cultured overnight,
followed by two additional panning cycles. After the third panning,
approximately 20 clones were subjected to the Western blot analysis in
order to identify positive clones.
For determining the nucleotide sequence of the positive clones, DNA
fragments spanning the random-peptide-encoding region
were first
amplified by PCR using primers FliTrx-2
(5'-TCACCGGTGGTGATAACGAT-3')
and RSR-2
(5'-CGATGTTCAGTTTTGCAACG-3'). The amplified fragment
was
then directly sequenced with a BigDye terminator kit (PE Biosystems)
primed by FliTrx-1 (5'-TTATTCACCTGACTGACGAC-3') for the
sense
strand or RSR-1 (5'-TTGCCCTGATATTCGTCAGCG-3') for the
antisense
strand, and the DNA sequence was analyzed by a Genetic
Analyzer
310 (PE
Biosystems).
 |
RESULTS |
Isolation of anti-NS3 MAbs.
Three stable hybridomas producing
high-affinity monoclonal IgG antibodies, designated as 7E3, 7E9, and
8D4, specific for the protease domain of NS3, were obtained by
immunization of mice with purified NS31-160 of
HCV-IIJ (20). Antibody subclasses of these MAbs
determined by use of a Mouse Mono AB ID kit (Zymed Laboratories) were
IgG1
.
Binding affinities of these antibodies to the full-length NS3 protease
(MBP-NS3
1-631) were first analyzed by monitoring
the
real-time binding with the surface plasmon resonance device
(IAsys
Biosensor). The equilibrium dissociation constants
(
Kd)
of MAbs were calculated from the ratio of
the kinetic rate constants
(Table
1). 8D4 showed the most profound
binding affinity (
Kd = 0.043 µM), whereas
7E3 showed moderate affinity (
Kd = 0.192
µM) to MBP-NS3
1-631 and 7E9 showed the weakest binding
affinity
(
Kd = 0.658 µM) among the three
MAbs (Table
1).
Effect of MAbs on NS3-dependent cleavage of polyproteins.
When the NS3/4A polyprotein was produced in vitro by use of
a coupled transcription-translation system, intramolecular
cleavage (cis processing) of the polyprotein at the NS3/4A
junction mediated by the NS3 protease was observed as assessed by
SDS-PAGE (Fig. 1A). The effect of MAbs on
this NS3-dependent cis-processing step was then examined to
compare the amounts of the cleavage products formed in the presence and
absence of 100 µg of each of the MAbs per ml. 8D4 appeared to be a
potent inhibitor of the cis-processing activity of NS3
protease (Fig. 1A, lane 5), but the other two MAbs (7E3 and 7E9) did
not show a significant effect at this concentration (Fig. 1A, lanes 3 and 4). The extent of 8D4 inhibition of cis-processing activity of NS3 was proportional to the concentration of 8D4 in the
reaction, and a 50% inhibitory concentration (IC50) of 10 µg/ml (67 nM) was obtained (Fig. 1B).

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of MAbs on polyprotein processing activity of NS3
protease. (A) NS3 protein (lane 1) or NS3/4A polyprotein in the absence
(lane 2) or presence of 100 µg of 7E3 (lane 3), 7E9 (lane 4), or 8D4
(lane 5)/ml was synthesized in vitro by a coupled
transcription-translation system for 2 h at 30°C, and the
NS3-dependent intramolecular cleavage of the polyprotein
(cis processing) was analyzed by SDS-PAGE. (B) Various
amounts of 8D4 were then added to the reaction, and the 8D4-mediated
inhibition of the cis-processing step of NS3 was evaluated.
The concentrations of 8D4 used were 0, 100, 50, 25, 12.5, 6.25, 3.13, and 1.56 µg/ml for lanes 1, 2, 3, 4, 5, 6, 7, and 8, respectively.
(C) The ability of MAbs to inhibit the NS3/4A protease-mediated
intermolecular cleavage (trans processing) of the
polyprotein at the NS5A/5B site was also examined. The polyprotein
containing the NS5A/5B cleavage site (NS5A N/5B), which encompassed
residues 2320 to 3011 of the HCV-IIJ polyprotein, was first
synthesized (lane 1). NS3/4A protease, which had been translated
without radiolabel in vitro, was preincubated at 30°C for 10 min in
the absence (lane 2) or presence of 7E3 (lane 3), 7E9 (lane 4), or 8D4
(lane 5) at an antibody concentration of 100 µg/ml. The reaction was
then initiated by the addition of a radiolabeled NS5A N/5B and was
incubated for 2 h at 30°C. Numbers on the left indicate the
apparent molecular masses that were determined by use of the prestained
(Bio-Rad Laboratories) or 14C-methylated (Amersham
Pharmacia Biotech) protein-molecular-weight markers in panels A and B
or C, respectively. Note that three or four additional bands seen in
the gels were degraded and/or incompletely translated polyproteins.
|
|
We also examined the ability of the MAbs to inhibit the NS3/4A
protease-mediated intermolecular cleavage (
trans processing)
of the polyprotein at the NS5A/5B junction. None of the MAbs tested,
however, showed any effect on
trans processing of the
polyprotein
at an antibody concentration of 100 µg/ml (Fig.
1C),
suggesting
the decreased sensitivity of NS3 to 8D4 in the presence of
the
NS4A
cofactor.
Effect of MAbs on NS3-dependent cleavage of a peptide
substrate.
We next assessed the abilities of these MAbs to inhibit
the NS3 protease activity toward a synthetic peptide
(Abz-EDVVECSMSY-NH2) containing the NS5A/5B cleavage site
as a substrate. Purified full-length NS3 protease
(MBP-NS31-631) was mixed with various amounts of MAbs,
and the residual protease activity was determined. All three MAbs
appeared to inhibit the cleavage of the substrate peptide under this
assay condition (Fig. 2A). The addition
of the NS4A peptide (Pep4A18-40), which comprised residues 18 to 40 of the NS4A protein and is known to increase the catalytic efficiency of NS3 protease (3, 13, 26, 35, 39), to the
reaction mixture decreased the inhibition potencies of all three MAbs
(Fig. 2A).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Effect of MAbs on NS3 protease activity toward a peptide
substrate. (A) Proteolytic activity of purified
MBP-NS31-631 was evaluated with a synthetic peptide
(2-Abz-EDVVECSMSY-NH2) that served as a substrate in the
presence or absence of MAbs. MBP-NS31-631 (22 nM) was
mixed with 0 (white bars), 11 (hatched bars), and 22 (gray bars) nM
concentrations of the indicated MAbs or a 22 nM concentration of the
indicated MAbs in the presence of 10 µM PepNS4A18-40
(H-LTTGSVVIVGRIILSGRPAVVPD-OH) (black bars). (B) The dose-dependent
inhibition by 8D4 of the proteolytic activity of the protease domain of
NS3 was also evaluated. His6-NS31-190 (38 nM)
was mixed with the indicated amounts of 8D4 in the absence ( ) or
presence ( ) of 15 µM PepNS4A18-40, and the residual
protease activities were determined. Note that the IC50s of
8D4 for His6-NS31-190 were 2.6 and 0.028 µM
in the presence and absence of PepNS4A18-40, respectively,
as obtained from the graph.
|
|
We further examined the extent of inhibition potencies of 8D4 in the
presence and absence of Pep4A
18-40 by using the
protease
domain of NS3 (His
6-NS3
1-190) as an enzyme
source
(Fig.
2B). The IC
50s of 8D4 for the
His
6-NS3
1-190 protease
were 0.028 and 2.6 µM
in the absence and presence of Pep4A
18-40,
respectively
(Fig.
2B). This 90-fold-decreased sensitivity of
NS3 to 8D4 by the
addition of Pep4A
18-40 appeared to be
consistent with the
data indicating that 8D4 had virtually no
effect on the
NS3/4A-dependent
trans processing of the NS5A/5B
polyprotein
(Fig.
1C) and may have been caused by the competition
between 8D4 and
Pep4A
18-40 for the identical binding site
in NS3 or by
decreased binding affinities as a result of the conformational
changes
in NS3 induced by its association with Pep4A
18-40.
Steady-state kinetic analysis of 8D4 inhibition of NS3
protease.
The cleavage of the substrate peptide mediated by the
full-length NS3 protease (MBP-NS31-631) was linear with
respect to time for at least 60 min in the absence of the NS4A cofactor after the initiation of the reaction (data not shown). Steady-state kinetic constants determined under this assay condition
(Km = 382 ± 14 µM;
kcat = 10.8 ± 1.6 min
1)
(Fig. 3A) were comparable to those
determined by others (35, 38). We then conducted the kinetic
experiments to analyze the inhibition mechanism of 8D4 in the absence
of Pep4A18-40. As shown in Fig. 3A, linear competitive
inhibition by 8D4 was observed for the proteolytic cleavage of the
peptide substrate by MBP-NS31-631, indicating that 8D4
directly blocked the binding of the substrate peptide in the absence of
the NS4A cofactor. The Ki value of 8D4
inhibition determined by the Dixon plot analysis was 39 nM (Fig. 3B),
in good agreement with the Kd value of 8D4 (Table 1).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Steady-state kinetic analysis of 8D4-mediated
inhibition. The reaction mixture containing 50 mM Tris-HCl (pH 8.5), 30 mM NaCl, 5 mM CaCl2, 10% glycerol, and 22 nM
MBP-NS31-631 protease was preincubated in the presence
or absence of various amounts of 8D4 for 10 min at room temperature,
and the reaction was then initiated by the addition of the substrate
peptide (2-Abz-EDVVECSMSY-NH2). After a 60-min incubation
at 37°C, the reaction was quenched by the addition of 0.5% TFA,
followed by separation and quantification of the cleavage product by
HPLC as described in Materials and Methods. Concentrations of the
substrate used were 0.2, 0.3, 0.4, 0.6, 0.8, and 1 mM; those of 8D4
were 0, 20, 40, and 60 nM. Data obtained were then analyzed by both
Lineweaver-Burk plot (A) and Dixon plot (B) analysis. The
Km and kcat values of
MBP-NS31-631 determined by the Lineweaver-Burk plot in
the absence of 8D4 were 382 ± 14 µM and 10.8 ± 1.6 min 1, respectively, and the Ki
value of 8D4 determined by the Dixon plot was 39 nM.
|
|
Determination of epitopes recognized by MAbs.
We next
attempted to identify epitopes recognized by these MAbs, using the
random peptide library displayed on the bacterial flagella. After three
rounds of panning cycles against each of the three MAbs, individual
colonies that were specifically stained by the corresponding antibody
in the Western blots were isolated (Fig.
4). Because the growth rates of the
bacteria and amounts of peptide-inserted thioredoxin-flagellin fusion
proteins produced in each of the isolated bacterial clones were
different, we used Anti-Thio antibody (Invitrogen), which specifically
recognizes thioredoxin, to normalize the amounts of the peptide-fusion
proteins. Binding affinities between the peptide fusion and 8D4 were
thus calculated as the relative band intensities of the Western blot by
dividing the intensities of bands stained with 8D4 by those of bands
stained with Anti-Thio antibody (Fig. 4B and C): values of relative
band intensities were 4.5, 0.58, 0.37, >22, and 0.0032 for clones 35, 38, 53 and 121 and the original library, respectively. The 121 clone
showed the most profound binding affinity with 8D4 in semiquantitative
Western blot analysis (Fig. 4C, lane 4), whereas virtually no band was
seen in the original library (Fig. 4C, lane 5).

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 4.
Western blot analysis of E. coli clones
selected for MAb 8D4. Cell lysates of E. coli clones
selected by binding to MAb 8D4 and that without panning (original
library) were analyzed on 12.5% acrylamide gels. Lanes 1, clone 35;
lanes 2, clone 38; lanes 3, clone 53; lanes 4, clone 121; lanes 5, original library. The gels stained with Coomassie brilliant blue (A)
and identical Western blots probed with anti-thioredoxin MAb (B) and
8D4 (C) are shown. The arrow indicates the peptide-inserted
thioredoxin-flagellin fusion proteins. Because the peptide library was
expressed as thioredoxin fusion proteins, intensities of bands detected
by the anti-thioredoxin MAb (Anti-Thio Antibody; Invitrogen) indicate
the amounts of peptide libraries produced in each of the isolated
clones. Relative binding affinities to 8D4 were thus determined to be
4.5, 0.58, 0.37, >22, and 0.0032 for clones 35, 38, 53, and 121 and
the original library, respectively, by dividing the band intensities
obtained with 8D4 by those obtained with anti-thioredoxin MAb.
|
|
Alignment of the deduced amino acid sequence derived from the
nucleotide sequence of the random-peptide-encoding region of
positive
clones allowed us to determine the consensus sequences,
GWP, RRRG, and
DxDLV, for MAbs 7E3, 7E9, and 8D4, respectively
(Fig.
5). These sequences strongly matched GWP,
RRRG, and DQDLV,
which correspond to residues 84 to 86, 117 to 120, and
79 to 83,
respectively, of the NS3 protease (Fig.
5), indicating
that each
of the MAbs recognized a sequential linear peptide chain as
its
epitope. It is noteworthy that one of the catalytic residues of
NS3 protease, Asp-81, is included in the candidate recognition
site
of 8D4 (Fig.
5).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
Amino acid sequences of the peptides displayed on
E. coli clones that were selected for MAbs. The deduced
amino acid sequences derived from the nucleotide sequences of the
random-peptide-encoding regions of isolated clones selected with 7E3,
7E9, and 8D4 are shown. Consensus amino acid residues are indicated in
bold, and the amino acid sequence of NS3 protease of
HCV-IIJ (20) that corresponds to the predicted
recognition site of each of the MAbs is given at the top.
|
|
In order to confirm that DQDLV residues of NS3 comprise the epitope
recognized by 8D4, we synthesized various 20-mer peptides
(Table
2) and tested their ability to compete
with MBP-NS3
1-631 in the binding reaction with 8D4.
8D4 was first preincubated with
each of the peptides or
MBP-NS3
1-631 for 1 h at room temperature
and then
transferred to a microtiter plate that had been coated
with
MBP-NS3
1-631, after which normal ELISA analysis was
conducted. The peptide carrying the sequence identical to amino
acid
residues 76 to 87 of NS3 (PepNS3) (Table
2) most significantly
blocked the ability of 8D4 to bind to MBP-NS3
1-631
(Fig.
6), whereas blockage occurred only
at much higher concentrations
of the peptides such as Pep8D4-35, -38, -53, and -121 that carried
the sequence derived from respective
8D4-reactive bacterial clones
(Table
2; Fig.
5). The extent of this
competition was proportional
to the concentration of the peptides used
in the preincubation,
indicating that both the peptides and
MBP-NS3
1-631 competed
for the same binding site of 8D4
(Fig.
6). It is of interest that
Pep8D4-35 showed poor ability for this
competition, although this
peptide contained the DQDLV motif,
suggesting that neighboring
residues may also be involved in the
recognition by 8D4.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Competitive ELISA analysis of the ability of synthetic
peptide to prevent binding between 8D4 and NS3 protease.
Approximately 100 ng of 8D4/ml was first preincubated with the
indicated concentrations of PepNS3 ( ), Pep8D4-35 ( ),
Pep8D4-38 ( ), Pep8D4-53 ( ), Pep8D4-121 ( ), or
MBP-NS31-631 ( ) for 1 h at room
temperature and then transferred to a microtiter plate that had been
coated with 10 ng of MBP-NS31-631. After thorough
washing with phosphate-buffered saline containing 0.05% Tween 20, MAbs
bound to the target antigen were labeled with biotinylated goat
anti-mouse IgG antibody and streptavidin-peroxidase conjugate and
detected with ortho-phenylenediamine as a substrate for the
peroxidase reaction. Peptide sequences used are given in Table 2.
|
|
 |
DISCUSSION |
HCV NS3 protease is an attractive target for the development
of anti-HCV agents, since NS3 is one of the virus-encoded proteases and has several properties that are clearly distinct from those of
related cellular enzymes (4, 11, 16, 18, 40). A number of
groups have described different approaches to investigating NS3
protease inhibitors, such as substrate or product mimetics (27,
37), high-throughput screening of chemical compounds (19), and a selection of affinity ligands from a large pool of macromolecular random libraries (8, 9, 22, 31).
Structure-based drug designs are a logical strategy for developing
inhibitors, especially because the three-dimensional and solution
structures of NS3 protease have been solved by X-ray
crystallography (21, 28) and NMR spectroscopy (1,
6), respectively. It is, however, reported that the relatively
featureless substrate-binding groove of NS3 protease would render
the design of low-molecular-weight inhibitors extremely challenging
(21). Immunochemical approaches employing MAbs are a useful
alternative method for providing structural templates for designing
low-molecular-weight lead compounds based on the
complementarity-determining regions (CDR) (10, 36). However,
the catalytic amino acids are mostly buried inside a cleft on the
enzyme's surface (25), and this part of the molecule is
regarded as having low immunogenicity (33, 34). In addition, the N-terminal portion of the NS3 protein has been shown to have low immunogenicity relative to that of the C terminus in both humans
and mice (5). Preparation of antibody with inhibition potency toward NS3 protease thus seems a daunting task. In fact, we
isolated only several MAbs that recognized the C-terminal region of
NS3 when full-length NS3 protein (NS31-631)
had been used to immunize mice (Y. Ohba, unpublished results). Martin
et al. (31) described a camelized VH domain
antibody inhibitor of NS3 protease isolated from a phage-displayed
synthetic repertoire, but the isolated proteins dimerized upon antigen
interaction, bringing into question their potential and the
single-domain nature of these proteins. Dimasi et al. (8)
also described a minibody ("minimized" antibody-like protein)
inhibitor of NS3 protease, but isolated minibodies showed
relatively low affinity for NS3 protease.
In the present study, we isolated a series of MAbs by screening
of hybridomas prepared from mice immunized with
NS31-160 and extensively characterized one of these
MAbs, 8D4. This MAb showed potent affinities both for binding to
MBP-NS31-631 and for competitive inhibition of its
protease activity with Kd and
Ki values of 43 and 39 nM, respectively. 8D4
also displayed substantial inhibition potency toward polyprotein
processing activity of NS3 in cis. Furthermore, detailed
epitope mapping demonstrated that the reactive site of 8D4 included the
catalytic residue Asp-81, clearly indicating the mechanism of
inhibition of NS3 protease mediated by 8D4. It is thus interesting
that 8D4 serves as a structural template for designing
low-molecular-weight lead compounds that target the active site of
NS3. In this regard, we have isolated genes for MAb 8D4 to
determine the deduced amino acid sequences of CDRs, and a study
focusing on the design of peptide analogs derived from the CDR residues
of 8D4 is now in progress.
It has been proposed that MAbs be used as conformation-dependent
reagents for investigating the structure of a protein, changes in its
conformation, and its folding mechanism (15). We found in
this study that the addition of the NS4A peptide,
Pep4A18-40, to the reaction significantly reduced the
inhibition potency of 8D4, indicating decreased binding affinity of 8D4
to the NS3/Pep4A18-40 complex. This is most likely due
to the repositioning or conformational rearrangements of the
8D4-binding site containing Asp-81 of the NS3 protease induced
by association with NS4A, consistent with the recent X-ray
crystallographic studies showing that interaction with NS4A involves
both a structural reorganization of the N-terminal domain and a
rearrangement of the catalytic triad of NS3 protease (21, 29,
41). Specifically, the Asp-81 side chain is oriented away from
His-57 in the NS3 crystal structure in the absence of the NS4A
cofactor (28), whereas Asp-81 moves closer to Ser-139 and
their side chains adopt a more chymotrypsin-like orientation in the
presence of the NS4A peptide (21). On the other hand, the
average solution structure of NS3 with or without the NS4A cofactor
determined by NMR spectroscopy showed that the strands E1 to F1 bearing
the Asp-81 residue are similarly positioned despite the lack of
experimental constraints of this region (1). Moreover, Landro et al. (24) have demonstrated that the pH dependence of the NS3 hydrolysis reaction is not affected by the presence of
NS4A, indicating that the presence of NS4A has no substantial effect on
the pKa of the catalytic residues. In any event, it is
evident that structural configurations of Asp-81 and neighboring residues, whether in the presence or absence of the NS4A cofactor, play
a critical role in the catalytic function of the NS3 protease. Kinetic and structural analysis of the binding of the protein complex
(NS3, 8D4, and/or NS4A) may allow us to elucidate the detailed
nature of the function of Asp-81 and neighboring residues in the
NS3 protease catalytic activity, as well as that of the inhibitory
activity of 8D4.
It has been shown that NS3 protease-mediated processing of HCV
polyprotein at the NS3/4A, NS4A/4B, and NS4B/5A sites is dependent on the NS4A cofactor, whereas processing at the NS5A/5B site occurs in
its absence but is significantly increased by this cofactor (3,
13, 26, 39). Among these sites, processing at the NS3/4A site
is an intramolecular reaction, as evidenced by the absence of
detectable NS3/4A precursors after a brief pulse-labeling period,
the inability to cleave the NS3/4A site in trans, and the insensitivity of cleavage kinetics at this site to dilution (3, 4, 26, 40). Although Failla et al. (12)
reported that cis-processing activity of the NS3
protease at the NS3/4A site is not affected even when the
NS4A-interaction site of NS3 is removed by the truncation of 28 N-terminal residues, it is not clear yet whether the NS4A cofactor is
required for the cis-processing reaction of NS3 at this
site, since the cofactor is covalently linked to the protease,
compensating for a defective protein-protein surface interaction. Our
finding, however, that only the cis-processing activity of
the NS3 protease at the NS3/4A site is inhibited by 8D4, which specifically recognizes NS3 but not the NS3/4A
complex, strongly suggests that the NS3 protease cleaves this
site prior to forming a complex with NS4A. It is thus likely that
different conformational states of NS3 protease are responsible for
the HCV polyprotein processing at different sites. This MAb 8D4
represents an interesting tool for investigating the mechanism and
pathway of NS3-dependent HCV polyprotein processing in HCV-infected cells.
It is noteworthy that both 7E3 and 7E9 inhibited the protease activity
of NS3 as assessed with a peptide but not with in vitro-translated polyproteins as substrates. It may be possible that the NS3
protease fused with MBP used in the assay has a specific conformation
enabling both MAbs to bind, although binding affinities of those MAbs
to MBP-NS31-631 appeared to be somewhat weaker than
the affinity of 8D4. Alternatively, it may also be likely that both
MAbs recognized the NS3 protease when it was complexed with the
peptide substrate but not with the polyproteins. In this regard, it is
worth noting that 117RRRG (amino acid residues that
comprise the epitope recognized by 7E9) has been shown to form a loop
between the
strands B2 and C2 (21, 28). This loop has
been thought to play a role in maintaining a well-defined
substrate-binding channel of NS3 as observed in alpha-lytic
protease (14, 21) and has been predicted to contain the zinc
ion coordination site (Cys-145 and His-149) that plays a role in
structural stabilization of NS3 (7). This loop of
NS3 has also been reported to be 14 to 15 residues shorter than
that of chymotrypsin or alpha-lytic protease, resulting in a relatively
solvent-exposed substrate-binding channel (21, 28). Indeed,
kinetic analysis of inhibition by 7E9 of MBP-NS31-631
showed a competitive manner with respect to the substrate peptide (M. Misawa, unpublished results), indicating that 7E9 has an ability to
directly block the binding of the substrate peptide to the NS3
protease. It will thus be interesting to elucidate the functions of the
loop and three consecutive arginine residues located at the
strands
B2 and C2 in the substrate specificity of NS3 protease and its
interactions with 7E9.
 |
ACKNOWLEDGMENTS |
We thank Isao Takahashi, Megumi Takase, and Rena Sekine for
excellent technical help and Nobuyoshi Chiba and Hiroyuki Morita for
helpful discussions throughout the course of this study. We also thank
Hirokazu Kurami and Toshimitsu Miyake for continued support.
 |
FOOTNOTES |
*
Corresponding author. Present address: Division of
Viral Immunology, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Kumamoto, 860-0811, Japan. Phone: 81-96-373-6530. Fax: 81-96-373-6532. E-mail:
uenot{at}kaiju.medic.kumamoto-u.ac.jp.
 |
REFERENCES |
| 1.
|
Barbato, G.,
D. O. Cicero,
M. C. Nardi,
C. Steinkuhler,
R. Cortese,
R. De Francesco, and R. Bazzo.
1999.
The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism.
J. Mol. Biol.
289:371-384[CrossRef][Medline].
|
| 2.
|
Bartenschlager, R.
1997.
Molecular targets in inhibition of hepatitis C virus replication.
Antivir. Chem. Chemother.
8:281-301.
|
| 3.
|
Bartenschlager, R.,
L. Ahlborn-Laake,
J. Mous, and H. Jacobsen.
1994.
Kinetic and structural analyses of hepatitis C virus polyprotein processing.
J. Virol.
68:5045-5055[Abstract/Free Full Text].
|
| 4.
|
Bartenschlager, R.,
L. Ahlborn-Laake,
J. Mous, and H. Jacobsen.
1993.
Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions.
J. Virol.
67:3835-3844[Abstract/Free Full Text].
|
| 5.
|
Chen, M.,
M. Sallberg,
A. Sonnerborg,
L. Jin,
A. Birkett,
D. Peterson,
O. Weiland, and D. R. Milich.
1998.
Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein.
Hepatology
28:219-224[CrossRef][Medline].
|
| 6.
|
Cicero, D. O.,
G. Barbato,
U. Koch,
P. Ingallinella,
E. Bianchi,
M. C. Nardi,
C. Steinkuhler,
R. Cortese,
V. Matassa,
R. De Francesco,
A. Pessi, and R. Bazzo.
1999.
Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies.
J. Mol. Biol.
289:385-396[CrossRef][Medline].
|
| 7.
|
De Francesco, R.,
A. Urbani,
M. C. Nardi,
L. Tomei,
C. Steinkuhler, and A. Tramontano.
1996.
A zinc binding site in viral serine proteinases.
Biochemistry
35:13282-13287[CrossRef][Medline].
|
| 8.
|
Dimasi, N.,
F. Martin,
C. Volpari,
M. Brunetti,
G. Biasiol,
S. Altamura,
R. Cortese,
R. De Francesco,
C. Steinkühler, and M. Sollazzo.
1997.
Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.
J. Virol.
71:7461-7469[Abstract].
|
| 9.
|
Dimasi, N.,
A. Pasquo,
F. Martin,
S. Di Marco,
C. Steinkuhler,
R. Cortese, and M. Sollazzo.
1998.
Engineering, characterization and phage display of hepatitis C virus NS3 protease and NS4A cofactor peptide as a single-chain protein.
Protein Eng.
11:1257-1265[Abstract/Free Full Text].
|
| 10.
|
Dougall, W. C.,
N. C. Peterson, and M. I. Greene.
1994.
Antibody-structure-based design of pharmacological agents.
Trends Biotechnol.
12:372-379[CrossRef][Medline].
|
| 11.
|
Eckart, M. R.,
M. Selby,
F. Masiarz,
C. Lee,
K. Berger,
K. Crawford,
C. Kuo,
G. Kuo,
M. Houghton, and Q. L. Choo.
1993.
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.
Biochem. Biophys. Res. Commun.
192:399-406[CrossRef][Medline].
|
| 12.
|
Failla, C.,
L. Tomei, and R. De Francesco.
1995.
An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A.
J. Virol.
69:1769-1777[Abstract].
|
| 13.
|
Failla, C.,
L. Tomei, and R. De Francesco.
1994.
Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins.
J. Virol.
68:3753-3760[Abstract/Free Full Text].
|
| 14.
|
Fujinaga, M.,
L. T. J. Delbaere,
G. D. Brayer, and M. N. G. James.
1985.
Refined structure of alpha-lytic protease at 1.7 A resolution: analysis of hydrogen bonding and solvent structure.
J. Mol. Biol.
184:479-502[CrossRef][Medline].
|
| 15.
|
Goldberg, M. E.
1991.
Investigating protein conformation, dynamics, and folding with monoclonal antibodies.
Trends Biochem. Sci.
16:358-362[CrossRef][Medline].
|
| 16.
|
Grakoui, A.,
D. W. McCourt,
C. Wychowski,
S. M. Feinstone, and C. M. Rice.
1993.
Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites.
J. Virol.
67:2832-2843[Abstract/Free Full Text].
|
| 17.
|
Hibino, T.,
S. Misawa,
M. Wakiyama,
S. Maeda,
K. Yazaki,
I. Kumagai,
T. Ooi, and K. Miura.
1994.
High-level expression of porcine muscle adenylate kinase in Escherichia coli: effects of the copy number of the gene and the translational initiation signals.
J. Biotechnol.
32:139-148[CrossRef][Medline].
|
| 18.
|
Hijikata, M.,
H. Mizushima,
T. Akagi,
S. Mori,
N. Kakiuchi,
N. Kato,
T. Tanaka,
K. Kimura, and K. Shimotohno.
1993.
Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus.
J. Virol.
67:4665-4675[Abstract/Free Full Text].
|
| 19.
|
Kakiuchi, N.,
Y. Komoda,
K. Komoda,
N. Takeshita,
S. Okada,
T. Tani, and K. Shimotohno.
1998.
Non-peptide inhibitors of HCV serine proteinase.
FEBS Lett.
421:217-220[CrossRef][Medline].
|
| 20.
|
Kato, N.,
M. Hijikata,
Y. Ootsuyama,
M. Nakagawa,
S. Ohkoshi,
T. Sugimura, and K. Shimotohno.
1990.
Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.
Proc. Natl. Acad. Sci. USA
87:9524-9528[Abstract/Free Full Text].
|
| 21.
|
Kim, J. L.,
K. A. Morgenstern,
C. Lin,
T. Fox,
M. D. Dwyer,
J. A. Landro,
S. P. Chambers,
W. Markland,
C. A. Lepre,
E. T. O'Malley,
S. L. Harbeson,
C. M. Rice,
M. A. Murcko,
P. R. Caron, and J. A. Thomson.
1996.
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide.
Cell
87:343-355[CrossRef][Medline].
|
| 22.
|
Kumar, P. K.,
K. Machida,
P. T. Urvil,
N. Kakiuchi,
D. Vishnuvardhan,
K. Shimotohno,
K. Taira, and S. Nishikawa.
1997.
Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA.
Virology
237:270-282[CrossRef][Medline].
|
| 23.
|
Kwong, A. D.,
J. L. Kim,
G. Rao,
D. Lipovsek, and S. A. Raybuck.
1998.
Hepatitis C virus NS3/4A protease.
Antivir. Res.
40:1-18[CrossRef][Medline].
|
| 24.
|
Landro, J. A.,
S. A. Raybuck,
Y. P. C. Luong,
E. T. O'Malley,
S. L. Harbeson,
K. A. Morgenstern,
G. Rao, and D. J. Livingston.
1997.
Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
Biochemistry
36:9340-9348[CrossRef][Medline].
|
| 25.
|
Laskowski, R. A.,
N. M. Luscombe,
M. B. Swindells, and J. M. Thornton.
1996.
Protein clefts in molecular recognition and function.
Protein Sci.
5:2438-2452[Medline].
|
| 26.
|
Lin, C.,
B. M. Prágai,
A. Grakoui,
J. Xu, and C. M. Rice.
1994.
Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics.
J. Virol.
68:8147-8157[Abstract/Free Full Text].
|
| 27.
|
Llinas-Brunet, M.,
M. Bailey,
G. Fazal,
S. Goulet,
T. Halmos,
S. Laplante,
R. Maurice,
M. Poirier,
M. A. Poupart,
D. Thibeault,
D. Wernic, and D. Lamarre.
1998.
Peptide-based inhibitors of the hepatitis C virus serine protease.
Bioorg. Med. Chem. Lett.
8:1713-1718[CrossRef][Medline].
|
| 28.
|
Love, R. A.,
H. E. Parge,
J. A. Wickersham,
Z. Hostomsky,
N. Habuka,
E. W. Moomaw,
T. Adachi, and Z. Hostomska.
1996.
The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.
Cell
87:331-342[CrossRef][Medline].
|
| 29.
|
Love, R. A.,
H. E. Parge,
J. A. Wickersham,
Z. Hostomsky,
N. Habuka,
E. W. Moomaw,
T. Adachi,
S. Margosiak,
E. Dagostino, and Z. Hostomska.
1998.
The conformation of hepatitis C virus NS3 proteinase with and without NS4A: a structural basis for the activation of the enzyme by its cofactor.
Clin. Diagn. Virol.
10:151-156[CrossRef][Medline].
|
| 30.
|
Lu, Z.,
K. S. Murray,
V. V. Cleave,
E. R. LaVallie,
M. L. Stahl, and J. M. McCoy.
1995.
Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions.
Bio/Technology
13:366-372[CrossRef][Medline].
|
| 31.
|
Martin, F.,
C. Volpari,
C. Steinkuhler,
N. Dimasi,
M. Brunetti,
G. Biasiol,
S. Altamura,
R. Cortese,
R. De Francesco, and M. Sollazzo.
1997.
Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease.
Protein Eng.
10:607-614[Abstract/Free Full Text].
|
| 32.
|
Miltenyi, S.,
W. Muller,
W. Weichel, and A. Radbruch.
1990.
High gradient magnetic cell separation with MACS.
Cytometry
11:231-238[CrossRef][Medline].
|
| 33.
|
Novotny, J.
1991.
Protein antigenicity: a thermodynamic approach.
Mol. Immunol.
28:201-207[CrossRef][Medline].
|
| 34.
|
Sheriff, S., and K. L. Constantine.
1996.
Redefining the minimal antigen-binding fragment.
Nat. Struct. Biol.
3:733-736[CrossRef][Medline].
|
| 35.
|
Shimizu, Y.,
K. Yamaji,
Y. Masuho,
T. Yokota,
H. Inoue,
K. Sudo,
S. Satoh, and K. Shimotohno.
1996.
Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by hepatitis C virus NS3 protease.
J. Virol.
70:127-132[Abstract].
|
| 36.
|
Sollazzo, M.
1995.
From protein engineering to drug design: imitating how antibodies do it.
Immunologist
3:5-11.
|
| 37.
|
Steinkuhler, C.,
G. Biasiol,
M. Brunetti,
A. Urbani,
U. Koch,
R. Cortese,
A. Pessi, and R. De Francesco.
1998.
Product inhibition of the hepatitis C virus NS3 protease.
Biochemistry
37:8899-8905[CrossRef][Medline].
|
| 38.
|
Steinkuhler, C.,
A. Urbani,
L. Tomei,
G. Biasiol,
M. Sardana,
E. Bianchi,
A. Pessi, and R. De Francesco.
1996.
Activity of purified hepatitis C virus protease NS3 on peptide substrates.
J. Virol.
70:6694-6700[Abstract/Free Full Text].
|
| 39.
|
Tanji, Y.,
M. Hijikata,
S. Satoh,
T. Kaneko, and K. Shimotohno.
1995.
Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing.
J. Virol.
69:1575-1581[Abstract].
|
| 40.
|
Tomei, L.,
C. Failla,
E. Santolini,
R. De Francesco, and N. La Monica.
1993.
NS3 is a serine protease required for processing of hepatitis C virus polyprotein.
J. Virol.
67:4017-4026[Abstract/Free Full Text].
|
| 41.
|
Yan, Y.,
Y. Li,
S. Munshi,
V. Sardana,
J. L. Cole,
M. Sardana,
C. Steinkuhler,
L. Tomei,
R. De Francesco,
L. C. Kuo, and Z. Chen.
1998.
Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form.
Protein Sci.
7:837-847[Medline].
|
Journal of Virology, July 2000, p. 6300-6308, Vol. 74, No. 14
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Prabhu, R., Khalap, N., Burioni, R., Clementi, M., Garry, R. F., Dash, S.
(2004). Inhibition of Hepatitis C Virus Nonstructural Protein, Helicase Activity, and Viral Replication by a Recombinant Human Antibody Clone. Am. J. Pathol.
165: 1163-1173
[Abstract]
[Full Text]